255 related articles for article (PubMed ID: 22143985)
1. Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells.
Blixt O; Lavrova OI; Mazurov DV; Cló E; Kracun SK; Bovin NV; Filatov AV
Glycobiology; 2012 Apr; 22(4):529-42. PubMed ID: 22143985
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer.
Mazal D; Lo-Man R; Bay S; Pritsch O; Dériaud E; Ganneau C; Medeiros A; Ubillos L; Obal G; Berois N; Bollati-Fogolin M; Leclerc C; Osinaga E
Cancer Immunol Immunother; 2013 Jun; 62(6):1107-22. PubMed ID: 23604173
[TBL] [Abstract][Full Text] [Related]
3. Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo.
Ando H; Matsushita T; Wakitani M; Sato T; Kodama-Nishida S; Shibata K; Shitara K; Ohta S
Biol Pharm Bull; 2008 Sep; 31(9):1739-44. PubMed ID: 18758069
[TBL] [Abstract][Full Text] [Related]
4. Role of O-glycosylation and expression of CD43 and CD45 on the surfaces of effector T cells in human T cell leukemia virus type 1 cell-to-cell infection.
Mazurov D; Ilinskaya A; Heidecker G; Filatov A
J Virol; 2012 Mar; 86(5):2447-58. PubMed ID: 22171268
[TBL] [Abstract][Full Text] [Related]
5. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens.
O'Boyle KP; Markowitz AL; Khorshidi M; Lalezari P; Longenecker BM; Lloyd KO; Welt S; Wright KE
Hybridoma; 1996 Dec; 15(6):401-8. PubMed ID: 8985750
[TBL] [Abstract][Full Text] [Related]
6. Early ovariectomy reveals the germline encoding of natural anti-A- and Tn-cross-reactive immunoglobulin M (IgM) arising from developmental O-GalNAc glycosylations. (Germline-encoded natural anti-A/Tn cross-reactive IgM).
Arend P
Cancer Med; 2017 Jul; 6(7):1601-1613. PubMed ID: 28580709
[TBL] [Abstract][Full Text] [Related]
7. Specificity of human natural antibodies referred to as anti-Tn.
Dobrochaeva K; Khasbiullina N; Shilova N; Antipova N; Obukhova P; Ovchinnikova T; Galanina O; Blixt O; Kunz H; Filatov A; Knirel Y; LePendu J; Khaidukov S; Bovin N
Mol Immunol; 2020 Apr; 120():74-82. PubMed ID: 32087569
[TBL] [Abstract][Full Text] [Related]
8. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
9. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
10. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
[TBL] [Abstract][Full Text] [Related]
12. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.
Reddish MA; Jackson L; Koganty RR; Qiu D; Hong W; Longenecker BM
Glycoconj J; 1997 Aug; 14(5):549-60. PubMed ID: 9298687
[TBL] [Abstract][Full Text] [Related]
13. Products of Chemoenzymatic Synthesis Representing MUC1 Tandem Repeat Unit with T-, ST- or STn-antigen Revealed Distinct Specificities of Anti-MUC1 Antibodies.
Yoshimura Y; Denda-Nagai K; Takahashi Y; Nagashima I; Shimizu H; Kishimoto T; Noji M; Shichino S; Chiba Y; Irimura T
Sci Rep; 2019 Nov; 9(1):16641. PubMed ID: 31719620
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a heterogeneous group of human breast carcinoma associated glycoproteins bearing the Tn determinant.
Osinaga E; Pancino G; Porchet N; Berois N; De Cremoux P; Mistro D; Aubert JP; Calvo F; Roseto A
Breast Cancer Res Treat; 1994; 32(2):139-52. PubMed ID: 7532464
[TBL] [Abstract][Full Text] [Related]
15. Production and functional characterization of two mouse/human chimeric antibodies with specificity for the tumor-associated Tn-antigen.
Oppezzo P; Osinaga E; Tello D; Bay S; Cantacuzene D; Irigoín F; Ferreira A; Roseto A; Cayota A; Alzari P; Pritsch O
Hybridoma; 2000 Jun; 19(3):229-39. PubMed ID: 10952411
[TBL] [Abstract][Full Text] [Related]
16. Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies.
Matsumoto Y; Kudelka MR; Hanes MS; Lehoux S; Dutta S; Jones MB; Stackhouse KA; Cervoni GE; Heimburg-Molinaro J; Smith DF; Ju T; Chaikof EL; Cummings RD
Glycobiology; 2020 Apr; 30(5):282-300. PubMed ID: 31742337
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
